New Frontiers in the Treatment and Management of Heart Failure: A Closer Look at the Role of Emerging Therapies is a two-part webinar series

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of heart failure

These are archives of live webinars held between May 12, 2021 to May 19, 2021.
If you participated in any of the live webinars, you are not eligible
to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from June 1, 2021 to June 1, 2023


This series is supported by an educational grant from
Merck Sharp & Dohme Corp.


 
Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. Projections show that by 2030, the prevalence of heart failure will increase 46 percent from recent estimates. HF is the reason for more than 1 million hospitalizations per year and an estimated $31 billion in costs in the U.S. each year. Fortunately for patients with HF, new and emerging therapeutic options have improved both clinical and economic outcomes for these patients and the system.


New Frontiers in the Treatment and Management of Heart Failure: A Closer Look at the Role of New Therapies

  1. Examine the unmet clinical needs in heart failure and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity
  2. Review the latest clinical evidence regarding the safety and efficacy of sGC modulators for treating patients with HF with reduced ejection fraction (HFrEF)
  3. Assess the role of sGC modulators and how they fit into current treatment paradigms for the management of HF
  4. Summarize evidence of HF interventions shown to reduce hospitalizations, morbidity, and mortality
       Physician, Nursing and CMCN credits valid to June 1, 2023

Recent Advances in the Treatment and Management of Heart Failure: Managed Care Considerations on New and Emerging Therapies

  1. Characterize the disease burden of HF in the managed care setting as determined by hospitalizations and other components of morbidity and mortality
  2. Analyze what managed care and payers need to know about newer therapies in heart failure management
  3. Examine the latest clinical evidence regarding the safety and efficacy of sGC modulators for treating patients with HF with reduced ejection fraction (HFrEF)
  4. Discuss current economic and logistic barriers to appropriate HF therapy in the managed care setting
  5. Apply methods to enable optimal cost management of newer heart failure therapy to be realized by multiple heart failure stakeholders including managed care organizations
       Physician, Nursing and CMCN credits valid to June 1, 2023